Isobavachalcone, a natural sirtuin 2 inhibitor, exhibits anti‐triple‐negative breast cancer efficacy in vitro and in vivo

Fuente: Wiley Open Access
Enregistré dans:
Détails bibliographiques
Auteurs principaux: Ya‐li Ren, Jie‐ting Lei, Ting‐rui Zhang, Peng Lu, Dan‐dan Cui, Bo Yang, Gui‐ying Zhao, Fu Peng, Zhi‐xing Cao, Cheng Peng, Yu‐zhi Li
Format: Artículo Open Access
Publié: Wiley 2024
Sujets:
Accès en ligne:
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
_version_ 1867014572987121664
author Ya‐li Ren
Jie‐ting Lei
Ting‐rui Zhang
Peng Lu
Dan‐dan Cui
Bo Yang
Gui‐ying Zhao
Fu Peng
Zhi‐xing Cao
Cheng Peng
Yu‐zhi Li
author_facet Ya‐li Ren
Jie‐ting Lei
Ting‐rui Zhang
Peng Lu
Dan‐dan Cui
Bo Yang
Gui‐ying Zhao
Fu Peng
Zhi‐xing Cao
Cheng Peng
Yu‐zhi Li
Ya‐li Ren
Jie‐ting Lei
Ting‐rui Zhang
Peng Lu
Dan‐dan Cui
Bo Yang
Gui‐ying Zhao
Fu Peng
Zhi‐xing Cao
Cheng Peng
Yu‐zhi Li
collection Wiley Open Access
contents Isobavachalcone, a natural sirtuin 2 inhibitor, exhibits anti‐triple‐negative breast cancer efficacy in vitro and in vivo Ya‐li Ren Jie‐ting Lei Ting‐rui Zhang Peng Lu Dan‐dan Cui Bo Yang Gui‐ying Zhao Fu Peng Zhi‐xing Cao Cheng Peng Yu‐zhi Li Phytotherapy Research AbstractTriple‐negative breast cancer (TNBC) is the most aggressive and lethal clinical subtype and lacks effective targeted therapies at present. Isobavachalcone (IBC), the main active component of Psoralea corylifolia L., has potential anticancer effects. Herein, we identified IBC as a natural sirtuin 2 (SIRT2) inhibitor and characterized the potential mechanisms underlying the inhibition of TNBC. Molecular dynamics analysis, enzyme activity assay, and cellular thermal shift assay were performed to evaluate the combination of IBC and SIRT2. The therapeutic effects, mechanism, and safety of IBC were analyzed in vitro and in vivo using cellular and xenograft models. IBC effectively inhibited SIRT2 enzyme activity with an IC50 value of 0.84 ± 0.22 μM by forming hydrogen bonds with VAL233 and ALA135 within its catalytic domain. In the cellular environment, IBC bound to and stabilized SIRT2, consequently inhibiting cellular proliferation and migration, and inducing apoptosis and cell cycle arrest by disrupting the SIRT2/α‐tubulin interaction and inhibiting the downstream Snail/MMP and STAT3/c‐Myc pathways. In the in vivo model, 30 mg/kg IBC markedly inhibited tumor growth by targeting the SIRT2/α‐tubulin interaction. Furthermore, IBC exerted its effects by inducing apoptosis in tumor tissues and was well‐tolerated. IBC alleviated TNBC by targeting SIRT2 and triggering the reactive oxygen species ROS/β‐catenin/CDK2 axis. It is a promising natural lead compound for future development of SIRT2‐targeting drugs. 10.1002/ptr.8143 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1002/ptr.8143
format Artículo Open Access
id wiley_oa_10_1002_ptr_8143
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2024
publisher Wiley
record_format wiley_oa
spellingShingle Isobavachalcone, a natural sirtuin 2 inhibitor, exhibits anti‐triple‐negative breast cancer efficacy in vitro and in vivo
Ya‐li Ren
Jie‐ting Lei
Ting‐rui Zhang
Peng Lu
Dan‐dan Cui
Bo Yang
Gui‐ying Zhao
Fu Peng
Zhi‐xing Cao
Cheng Peng
Yu‐zhi Li
Phytotherapy Research
Isobavachalcone, a natural sirtuin 2 inhibitor, exhibits anti‐triple‐negative breast cancer efficacy in vitro and in vivo Ya‐li Ren Jie‐ting Lei Ting‐rui Zhang Peng Lu Dan‐dan Cui Bo Yang Gui‐ying Zhao Fu Peng Zhi‐xing Cao Cheng Peng Yu‐zhi Li Phytotherapy Research AbstractTriple‐negative breast cancer (TNBC) is the most aggressive and lethal clinical subtype and lacks effective targeted therapies at present. Isobavachalcone (IBC), the main active component of Psoralea corylifolia L., has potential anticancer effects. Herein, we identified IBC as a natural sirtuin 2 (SIRT2) inhibitor and characterized the potential mechanisms underlying the inhibition of TNBC. Molecular dynamics analysis, enzyme activity assay, and cellular thermal shift assay were performed to evaluate the combination of IBC and SIRT2. The therapeutic effects, mechanism, and safety of IBC were analyzed in vitro and in vivo using cellular and xenograft models. IBC effectively inhibited SIRT2 enzyme activity with an IC50 value of 0.84 ± 0.22 μM by forming hydrogen bonds with VAL233 and ALA135 within its catalytic domain. In the cellular environment, IBC bound to and stabilized SIRT2, consequently inhibiting cellular proliferation and migration, and inducing apoptosis and cell cycle arrest by disrupting the SIRT2/α‐tubulin interaction and inhibiting the downstream Snail/MMP and STAT3/c‐Myc pathways. In the in vivo model, 30 mg/kg IBC markedly inhibited tumor growth by targeting the SIRT2/α‐tubulin interaction. Furthermore, IBC exerted its effects by inducing apoptosis in tumor tissues and was well‐tolerated. IBC alleviated TNBC by targeting SIRT2 and triggering the reactive oxygen species ROS/β‐catenin/CDK2 axis. It is a promising natural lead compound for future development of SIRT2‐targeting drugs. 10.1002/ptr.8143 http://onlinelibrary.wiley.com/termsAndConditions#vor
title Isobavachalcone, a natural sirtuin 2 inhibitor, exhibits anti‐triple‐negative breast cancer efficacy in vitro and in vivo
topic Phytotherapy Research
url https://onlinelibrary.wiley.com/doi/10.1002/ptr.8143